Search results
Added:
1 month ago
Added:
1 year ago
ESC Congress 2024 — FINEARTS-HF shows finerenone reduces cardiovascular death and total of worsening heart failure (HF) events over median follow-up of 32 months.Host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal investigator, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, US) to discuss findings from the landmark FINEARTS-HF trial (NCT04435626…
View more
Start date:
Nov 17, 2025
Breakthrough Mineralocorticoid Receptor Antagonists in Cardiovascular Care brings together renowned cardiovascular experts Dr Vijay Chopra, Dr Javed Butler, Dr Dinesh Khullar, and Prof John McMurray to address critical challenges in heart failure management and hypertension treatment. This comprehensive session explores innovative approaches to mineralocorticoid receptor antagonist (MRA) therapy,…
View more
Aldosterone and Potassium in Heart Failure
Added:
1 year ago
Review Article
Added:
1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
The Aldosterone Story: New Chapters
Added:
10 months ago
Editorial
Mineralocorticoid Receptor Antagonists in Heart Failure
Added:
1 year ago
Review Article
Finerenone: Will It Be a Game-changer?
Added:
1 year ago
Review Article
Aldosterone Synthase Inhibitors
Added:
9 months ago
Review Article
Pharmacological Therapy of HFrEF in 2025
Added:
10 months ago
Review Article